Latest Proton pump inhibitors Stories
Labeling changes will include new safety information SILVER SPRING, Md., May 25 /PRNewswire-USNewswire/ -- The U.S.
NEW ORLEANS, May 5 /PRNewswire/ -- What: Data results from a recent retrospective analysis of DEXILANT delayed release capsules and lansoprazole were presented at Digestive Disease Week (DDW) 2010 in New Orleans.
WILMINGTON, Del., April 30 /PRNewswire-FirstCall/ -- AstraZeneca and POZEN Inc. today announced the U.S.
DEERFIELD, Ill., April 26 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. today announced that DEXILANT(TM) (dexlansoprazole) delayed release capsules are now available in United States (U.S.) pharmacies.
New research by the University of East Anglia (UEA) shows no risk in combining two commonly-prescribed treatments for patients at risk of heart attacks and strokes.
ROCKVILLE, Md., March 15 /PRNewswire-USNewswire/ -- Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrel - a drug that prevents blood clots - were only half as likely to be hospitalized for upper digestive tract bleeding than those who used clopidogrel alone, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the National Heart, Lung, and Blood Institute at the National Institutes of Health.
DEERFIELD, Ill., March 4 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX(TM) (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT(TM) (dexlansoprazole).
DEERFIELD, Ill., Feb.
PARSIPPANY, N.J., Feb. 2 /PRNewswire/ -- With the Big Game approaching, many football fans across the country are preparing for viewing parties, and the non-stop eating that comes with them.
For years, the two most prevalent strategies for treating chronic gastroesophogeal reflux disease â€” commonly known as â€˜acid refluxâ€™ â€” have been prescription medications and surgery.